Mai Van-Hieu, Ponce-Zea Jorge Eduardo, Doan Thi-Phuong, Vu Quang Huy, Ryu Byeol, Lee Chul-Ho, Oh Won-Keun
Korea Bioactive Natural Material Bank, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.
J Nat Prod. 2024 Aug 23;87(8):1903-1913. doi: 10.1021/acs.jnatprod.4c00249. Epub 2024 Jul 24.
Four new compounds, racemic chalcone-monoterpene hybrids (-) and a chalcone (), along with nine known compounds (-, -), have been isolated from the buds of . The chemical structures of the isolated compounds were identified through NMR data analysis and confirmed by computational methods, including electronic circular dichroism (ECD) calculations, and further synthetic approaches. Compounds - were synthesized via a Diels-Alder reaction, a process informed by biomimetic condensation studies that combined chalcones and monoterpenes. These synthetic approaches also yielded various unnatural chalcone-monoterpene derivatives (-). The inhibitory effects on protein tyrosine phosphatase 1B (PTP1B) of both naturally isolated and synthetically obtained compounds were evaluated. Compounds , , , and exhibited potent PTP1B inhibitory activity, with IC values ranging from 0.9 ± 0.2 to 3.9 ± 0.7 μM. The enantiomers (+)- and (-)- showed enhanced activity compared to their respective enantiomers. Kinetic studies indicate that all active compounds inhibit PTP1B through mixed mechanisms, and molecular docking simulations agree with the experimental assays on PTP1B. Our results suggest that chalcone-meroterpene adducts from the buds of exhibit potential as antidiabetic agents, partly due to their PTP1B enzyme inhibition.
从[植物名称]的芽中分离出了四种新化合物,即外消旋查尔酮-单萜杂化物(-)和一种查尔酮(),以及九种已知化合物(-,-)。通过核磁共振数据分析确定了分离出的化合物的化学结构,并通过包括电子圆二色性(ECD)计算在内的计算方法以及进一步的合成方法进行了确认。化合物-通过狄尔斯-阿尔德反应合成,该过程是基于将查尔酮和单萜结合的仿生缩合研究。这些合成方法还产生了各种非天然的查尔酮-单萜衍生物(-)。评估了天然分离和合成获得的化合物对蛋白酪氨酸磷酸酶1B(PTP1B)的抑制作用。化合物、、、和表现出强大的PTP1B抑制活性,IC值范围为0.9±0.2至3.9±0.7μM。对映体(+)-和(-)-与其各自的对映体相比活性增强。动力学研究表明,所有活性化合物均通过混合机制抑制PTP1B,分子对接模拟与对PTP1B的实验测定结果一致。我们的结果表明,来自[植物名称]芽的查尔酮-单萜加合物具有作为抗糖尿病药物的潜力,部分原因是它们对PTP1B酶的抑制作用。